GlassScriptPhysician profile
Sarah A Cuffee
NPI 1134672330
$5,980.31
in general payments reported to CMS, 2019-2025
23 companies · $695 in 2025
The $695 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,554 · 2022: $1,678 · 2023: $1,782 · 2024: $271 · 2025: $695.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,721 · Education: $26.83.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,721.24 |
| Education | $26.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $903.77 | 2021-2025 | Jynarque |
| Astrazeneca Pharmaceuticals LP | $864.60 | 2021-2025 | Farxiga, Lokelma |
| Vifor Pharma, INC. | $810.05 | 2021-2023 | Veltassa, Korsuva |
| Amgen INC. | $773.54 | 2021-2025 | Tavneos, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $548.27 | 2021-2025 | |
| Aurinia Pharma U.S., INC. | $341.04 | 2021-2023 | Lupkynis |
| Glaxosmithkline, LLC. | $269.35 | 2021-2023 | Benlysta |
| Novartis Pharmaceuticals Corporation | $196.97 | 2021-2025 | |
| Travere Therapeutics, INC. | $196.97 | 2022-2024 | |
| Calliditas Therapeutics US INC. | $195.23 | 2022-2025 | Tarpeyo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $157.76 | 2023 | Jardiance |
| Mallinckrodt Hospital Products INC. | $150.27 | 2022-2025 | Terlivaz |
| Arbor Pharmaceuticals, INC. | $121.33 | 2021 | |
| Ardelyx, INC. | $114.02 | 2025 | Xphozah 30 Mg |
| Nxstage Medical, INC. | $94.78 | 2025 | Liberty Select Cycler, Nxstage System One, Nxstage Pureflow Solution |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $74.47 | 2021 | |
| Novo Nordisk INC | $42.77 | 2023-2024 | Ozempic |
| Recordati_rare_diseases_inc. | $27.75 | 2021 | |
| Lilly USA, LLC | $23.32 | 2023 | Jardiance |
| Alexion Pharmaceuticals, INC. | $20.42 | 2025 | Ultomiris |
| Daiichi Sankyo INC. | $19.31 | 2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $18.59 | 2023 | Jynarque |
| Akebia Therapeutics INC | $15.73 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Cuffee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.